Abstract
Provided is a use of CXCR4-targeted nanoparticle for the manufacture of pharmaceuticl composition for treatment of liver cancer and inhibition of metastasis. CXCR4 anatognist, AMD3100, is used as a targeting molecule to modify a lipid carrier for the formation of nanoparticle carrying anti-angiogenesis drug or anti-angiogentic nucleotide. Such nanoparticle can enhance the accumulation and uptake of said drug and nucleotide in liver cancer cells as well as sensitize the liver cancer cells to treatment of said drug and nucleotide, providing a synergistic suppression of angiogenesis and tumor progression. Furthermore, the CXCR4-targeted nanoparticle can effectively inhibit metastasis of liver cancer. The pharmaceutical composition is an injectable composition; hence, is suitable for clinical application for the treatment of liver cancer.